Nanoviricides (NNVC) Short term Debt (2016 - 2017)
Nanoviricides (NNVC) posted Short term Debt of $4.2 million for Q3 2017, up 6.05% sequentially from $4.0 million in Q2 2017, and down 26.25% YoY from $5.7 million in Q3 2016.
Nanoviricides (NNVC) Short term Debt (2016 - 2017) Analysis & Trends
Nanoviricides has reported Short term Debt for 2 years, with the latest figure at $4.2 million in Q3 2017.
- Quarterly Short term Debt fell 26.25% year-over-year to $4.2 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $4.2 million (down 26.25% YoY) and the FY2017 annual result came in at $4.0 million, changed N/A from the prior year.
- Short term Debt grew to $4.2 million in Q3 2017 per NNVC's latest filing, from $4.0 million in the prior quarter.
- Over five years, Short term Debt peaked at $5.9 million in Q4 2016 and troughed at $4.0 million in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Nanoviricides | 29.06 Mn | 25.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 4.20 Mn |
| Jun 30, 2017 | 3.96 Mn |
| Dec 31, 2016 | 5.91 Mn |
| Sep 30, 2016 | 5.69 Mn |
| Mar 31, 2016 | 5.27 Mn |